[NYC session] JLABS @ NYC: Get the Scoop
New York Genome Center , 101 6th Ave , New York , NY 10013
February 22, 2017 from 16:30 PM to 19:30 PM (EDT)
$10 - $35
Be first in line for the New JLABS @ NYC! Johnson & Johnson Innovation, New York State, and the NY Genome Center recently announced JLABS @ NYC, a 30,000-square foot facility that will support growth of healthcare solutions in the region by providing development and commercialization resources for emerging life science companies.
Johnson & Johnson Innovation seeks to find the best science and technology, no matter where it is located, to solve the greatest unmet medical and healthcare needs of our time. JLABS, in addition to offering emerging life science companies modular lab units, office space, shared core laboratory equipment and business facilities, will link the entrepreneurs of New York with the full breadth of Johnson & Johnson Innovation, including opportunities for funding, third-party services, educational events and R&D experts from medical technology, consumer healthcare product and Janssen pharmaceutical teams.
On February 22, get the scoop on JLABS @ NYC before anyone else. Hear from Johnson & Johnson Innovation leaders Kuldeep Neote, Senior Director of New Ventures, Charles Bridges, Vice President & Cardiovascular Therapeutic Area Expert, Johnson & Johnson Medical Devices, and Melinda Richter, Head of JLABS. These experts will provide an overview of J&J Innovation goals and mission, highlighting how Johnson & Johnson interacts with the community through JLABS. Don't miss this opportunity to learn more on the progress of this ground-breaking project.
3:30 PM | Registration opens, Networking
4:00 PM | Presentation
5:00 PM | Q&A
5:30 PM | Networking reception (light hors d'oeuvres will be served)
6:30 PM | Program Close
Johnson & Johnson Participating Representatives:
Kuldeep Neote | Sr Director, New Ventures, Johnson & Johnson Innovation read bio»
Melinda Richter | Head, Johnson & Johnson Innovation, JLABS read bio»
Charles Bridges | VP, Cardiovascular Therapeutic Area Expert, Johnson & Johnson Medical Devices Companies read bio»
New York Genome Center
101 6th Ave
New York, NY
Johnson & Johnson Participating Representatives' Biographies:
Kuldeep Neote, Ph.D. | Senior Director, New Ventures, Johnson & Johnson Innovation
Kuldeep is Senior Director of New Ventures at the Johnson & Johnson Innovation, Boston. He focuses primarily on the areas of Oncology and Immunology. A trained molecular biologist with an extensive background in drug discovery, Kuldeep has been focused on the areas of Immunology, Inflammation and Oncology and has a passion for implementing cutting edge scientific discoveries into practical drug discovery programs. Formerly, Kuldeep was Research Advisor/Director in Global External R&D at Eli Lilly. Prior to Eli Lilly, he was a Discovery Scientist at Pfizer, where he initiated the chemokine receptor drug discovery platform that led to the discovery and further development of several clinical candidates. Earlier in his career, Kuldeep also cloned one of the first chemokine receptors while at Genentech. Kuldeep earned his BSc. in Microbial and Cellular Biology at the University of Calgary, and a Ph.D. in Human and Molecule Genetics at the University of Toronto, where he was a major contributor in the understanding of the molecular basis of lysosomal storage diseases, in particular Tay Sachs and Sandhoff's disease.
Connect with Kuldeep:
Melinda Richter, Head, Johnson & Johnson Innovation, JLABS
As Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a biotech company.
Prior to joining JLABS, Melinda was Founder and CEO of Prescience International, an award-winning firm dedicated to accelerating research to the patient. Melinda founded Prescience after she had a medical emergency that left her questioning the efficiency and efficacy of the healthcare system. With the tenacity and resolve of a patient looking for a better solution, she set out to create a better model, which now forms the basis for JLABS’ operational infrastructure. Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also initiated, raised capital and secured large corporate deals for several companies in both the life science and technology space. She holds a Bachelor of Commerce from the University of Saskatchewan in Canada and a MBA from INSEAD in France.
Connect with Melinda:
Charles Bridges | Vice President, Cardiovascular Therapeutic Area Expert, Johnson & Johnson Medical Devices
Charles R. Bridges is the Vice President, Therapeutic Area Expert Cardiovascular for Medical Devices. In this role, he accelerates innovation, and advances the standard of care within early stage science to elevate existing and adjacent technologies
Charles is a board certified cardiothoracic surgeon and is an internationally recognized expert in cardiovascular gene therapy, blood conservation and transfusion-free cardiac surgery. He is responsible for identifying new technology platforms in cardiovascular devices that provide transformational innovation. Charles joined Johnson & Johnson from Carolinas Healthcare System where he was Chairman of the Department of Thoracic and Cardiovascular Surgery and Vice President of Cardiovascular Translational Research. He was previously Professor of Surgery at the University of Pennsylvania and Chief of Cardiac Surgery at Pennsylvania Hospital. A distinguished surgeon-scientist, he invented the concept of “molecular cardiac surgery”. Charles has received more than $10M in NIH funding and has over 160 peer-reviewed publications, twelve issued and pending U.S. and international patents for inventions in the fields of cardiovascular devices and cardiac and systemic gene and cell delivery. He has served as a consultant to the Circulatory System Devices Panel of the U.S. Food and Drug Administration and as a regular member of the Bioengineering, Technology and Surgical Sciences Study Section of NIH. He currently serves as a member of the Steering Committee of the Gene Therapy Resource Program (GTRP) of the National Heart Lung and Blood Institute, and as Chairman of the Cardiovascular Committee of the American Society for Cell and Gene Therapy.
Charles received an A.B. in Applied Physics from Harvard College magna cum laude at age 19 and an M.D. from Harvard Medical School in the Harvard-M.I.T. Program in Health Sciences and Technology. He received a Master of Science in Electrical Engineering and Computer Science and a Doctor of Science in Chemical Engineering from M.I.T. where he was elected to Sigma Xi as a Whittaker Health Sciences Fellow. He competed in the 2016 World (Rubik’s) Cube Association US Nationals competition.